{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=20", "query": { "intervention": "SC", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 3859, "total_pages": 386, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T11:54:21.138Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01987362", "title": "A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, Advanced Solid Tumors" ], "interventions": [ { "name": "RO6870810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2013-10-16", "completion_date": "2017-10-11", "has_results": false, "last_update_posted_date": "2018-01-05", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01987362" }, { "nct_id": "NCT03338816", "title": "ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Hepatic Porphyria", "Acute Intermittent Porphyria", "Porphyria, Acute Intermittent", "Acute Porphyria", "Hereditary Coproporphyria (HCP)", "Variegate Porphyria (VP)", "ALA Dehydratase Deficient Porphyria (ADP)" ], "interventions": [ { "name": "Givosiran", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 94, "start_date": "2017-11-16", "completion_date": "2021-05-31", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03338816" }, { "nct_id": "NCT07133633", "title": "A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Radiographic Axial Spondyloarthritis" ], "interventions": [ { "name": "Tulisokibart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 315, "start_date": "2025-09-26", "completion_date": "2030-02-05", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 37, "location_summary": "Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 33 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07133633" }, { "nct_id": "NCT01926782", "title": "Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Statin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 803, "start_date": "2013-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 49, "location_summary": "Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01926782" }, { "nct_id": "NCT07422480", "title": "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndrome", "Anemia" ], "interventions": [ { "name": "Elritercept", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2026-05-21", "completion_date": "2033-10-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 31, "location_summary": "Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07422480" }, { "nct_id": "NCT05032183", "title": "Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Lymphoblastic Lymphoma", "Refractory T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tagraxofusp-erzs", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2022-02-17", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032183" }, { "nct_id": "NCT05101356", "title": "A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Metastatic Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Adenocarcinoma", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Antineoplastic Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2021-01-13", "completion_date": "2034-01-01", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05101356" }, { "nct_id": "NCT01090661", "title": "A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "mipomersen sodium", "type": "DRUG" }, { "name": "moxifloxacin hydrochloride (Avelox®)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kastle Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2010-03", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2016-08-03", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01090661" }, { "nct_id": "NCT06145373", "title": "A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "Fitusiran (SAR439774)", "type": "DRUG" }, { "name": "Clotting factor concentrates (CFC) or bypassing agents (BPA)", "type": "BIOLOGICAL" }, { "name": "Antithrombin concentrate (ATIIIC)", "type": "BIOLOGICAL" }, { "name": "Emicizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "MALE", "summary": "12 Years and older · Male only" }, "enrollment_count": 20, "start_date": "2024-03-01", "completion_date": "2030-01-30", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 2, "location_summary": "Los Angeles, California • Flowood, Mississippi", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Flowood", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT06145373" }, { "nct_id": "NCT05136053", "title": "A Study Investigating Lu AG22515 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Lu AG22515", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Immune System Activator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "19 Years to 60 Years" }, "enrollment_count": 58, "start_date": "2022-03-18", "completion_date": "2023-08-05", "has_results": false, "last_update_posted_date": "2023-08-28", "last_synced_at": "2026-10-26T11:54:21.138Z", "location_count": 2, "location_summary": "Long Beach, California • Secaucus, New Jersey", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Secaucus", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05136053" } ] }